Licensing Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
LICENSING AGREEMENT by and Among BLACK STALLION OIL & GAS, INC. A Corporation Incorporated in the State of Delaware, ACTIVE LAB INTERNATIONAL, INC. A Corporation Incorporated in the State of Wyoming Dated as of August 8, 2017 LICENSING AGREEMENT (September 22nd, 2017)
Neurokine Pharmaceuticals Inc. – Pivot - Altum Licensing Agreement (September 13th, 2017)

This EXCLUSIVE LICENSING AGREEMENT is made this 12th day of September 2017 (hereinafter the "Effective Date"), by and between PIVOT PHARMACEUTICALS INC., a corporation organized under the laws of British Columbia with an address c/o Alexander Holburn Beaudin & Lang LLP at 2700-700 West Georgia Street, Vancouver, British Columbia V7Y 1B8 (hereinafter "PIVOT") and ALTUM PHARMACEUTICALS INC., a corporation organized under the laws of British Columbia with an address c/o 1275 West 6th Street, Suite 300, Vancouver, BC V6C 1V5 (hereinafter "ALTUM"). PIVOT and ALTUM herein may be referred to individually as "Party" or together as "Parties."

Palatin Technologies, Inc. – Palatin Technologies Announces Signing of Licensing Agreement With Fosun Pharma Rights to Bremelanotide in China and Other Selected Territories (September 7th, 2017)

CRANBURY, NJ - September 6, 2017 - Palatin Technologies, Inc. (NYSE MKT: PTN;"Palatin") announced today that it has entered into a collaboration and license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), for exclusive rights to develop and commercialize bremelanotide for female sexual dysfunction (FSD) indications in the territories of mainland China, Taiwan, Hong Kong S.A.R. and Macau S.A.R. Fosun Pharma is a leading Chinese healthcare provider with annual sales of more than $2 billion. Bremelanotide is an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Palatin previously announced positive Phase 3 results with bremelanotide for treating HSDD in premenopausal women. A New Drug Application (NDA) is anticipated to be filed with the U.S. Food and Drug Administration (FDA) in the first quarter of cale

WOWI, Inc. – WOWI Inc Licensing Agreement (August 11th, 2017)

This License Agreement (this "Agreement" of this "License Agreement") is made and effective as of 7/1/2015 (the "Commencement Date") by and between:

Insys Therapeutics Inc. – Amendment Number One to the Amended and Restated Supply, Development & Exclusive Licensing Agreement (August 7th, 2017)

THIS AMENDMENT NUMBER ONE ("Amendment Number 1") to the AMENDED AND RESTATED SUPPLY, DEVELOPMENT & EXCLUSIVE LICENSING AGREEMENT with an effective date of October 30, 2015 (the "A&R Agreement"), is hereby entered into as of April 6, 2017 with an effective date of January 1, 2017 ("Effective Date"), by and between INSYS MANUFACTURING, LLC, a Texas limited liability company, having its place of business at 1333 S. Spectrum Blvd., Suite 100, Chandler, AZ 85286 ("PURCHASER") and APTARGROUP, INC., a Delaware corporation, having its place of business at 475 West Terra Cotta Avenue, Suite E, Crystal Lake, IL 60014-9695 ("SELLER").

Pacificorp Holdings Ltd. – ADDENDUM "A" Addendum to Licensing Agreement (July 31st, 2017)

This is an addendum dated 25 July, 2017 to a Licensing Agreement ("Agreement") dated and amended on June 1, 2017 wherein AGHWA, LLC, ("Licensor"), agrees to License and Cannabis Leaf, Inc. ("Licensee"), agrees to the following revised terms.

Ophthalix Inc – Addition to the Amendment to Licensing Agreement - Worldwide Rights to the Unit Dose Eye Product - Dated November 22, 2015 (July 27th, 2017)

Subject to Wize Pharma exercising the Option mentioned in the Amendment to Licensing Agreement dated November 22, 2015 section 3, The minimal sales in every country will be based on the formula described in the Appendix E of the Eyedrops for the USA document signed May 1, 2015, except if different terms are agreed in advance, in writing with Resdevco.

Ophthalix Inc – Amendment No. 2 to Exclusive Distribution and Licensing Agreement Between Wize Pharma Ltd. (Formerly Star Night Technologies Ltd) and Resdevco Ltd. (July 27th, 2017)

This Amendment (the "Amendment") refers to the Exclusive Distribution and Licensing Agreement between Wize Pharma Ltd. ( the "Licensee") and Resdevco Ltd. (the "Licensor") signed on, May 1, 2015 as amended on November 22, 2015 (the "Agreement") and is entered into on the Execution Date (us defined below).

Ophthalix Inc – Amendment 2 to Licensing Agreement - Ukraine Market (July 27th, 2017)

1.This Amendment refers to the Exclusive Distribution and Licensing Agreement between Resdevco Ltd. and Wize Pharma (formerly: Star Night Technologies) signed on May 1, 2015 (hereinafter called the "Agreement") 2.Territory is extended to The Ukraine, therefore the term Territory refers to both the USA and the Ukraine markets. 3.If the Agreement is terminated for the USA Territory, this event will have no consequences on this Amendment with the original Agreement 4.The term "FDA" should be replaced by "Ministry of Health of Ukraine" throughout the Agreement 5.The r

Ophthalix Inc – Exclusive Distribution and Licensing Agreement (July 27th, 2017)
Ophthalix Inc – Appendix F to Exclusive Distribution and Licensing Agreement" Between Resdevco Ltd. And Wize Pharma Signed on May 1, 2015. This Appendix Replaces the Document of the Same Name Dated July 1, 2017 (July 27th, 2017)
Tesaro – Tesaro and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan (July 27th, 2017)

Takedas Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia

Ophthalix Inc – Second Addition to the Amendment to Licensing Agreement - Worldwide Rights to the Unit Dose Eye Product -- Dated November 22, 2015 (July 27th, 2017)
Ophthalix Inc – Amendment 1 to Licensing Agreement - Israeli Market (July 27th, 2017)
Ophthalix Inc – November 22, 2015 Amendment to Licensing Agreement - Worldwide Rights to the Unit Dose Eye Product (July 27th, 2017)

This Amendment refers to the Exclusive Distribution and Licensing Agreement between Resdevco Ltd. And Wize Pharma Ltd (Star Night Technologies Ltd) signed on, May 1, 2015 (hereinafter called the "Agreement")

Ophthalix Inc – Appendix G. To the Exclusive Distribution and Licensing Agreement, Dated May 1, 2015 July 20, 2017 (July 27th, 2017)

Resdevco Ltd. hereby declares that all its patents and trade names related to the LO2A unit dose eye drops may be used by Wize Phanna Ltd./ Ocu Wize Ltd. in the territories to which the Exclusive Distribution and Licensing Agreement, dated May 1, 2015 is extended (at present Israel and the Ukraine) as long as the contract for those territories is valid

HYBRID Coating Technologies Inc. – Thirteenth Amendment to the Licensing Agreement Previously Entered Into (June 20th, 2017)

Nanotech Industries International Inc., a Nevada corporation (and a wholly owned subsidiary of Hybrid Coating Technologies Inc.)

TERM SHEET FOR Prana Bio Nutrient Medicinals Distribution and Licensing Agreement (March 23rd, 2017)

This Term Sheet is to definitively agree to a Distribution and Licensing Agreement by and between UCANN California Corporation, (UCANN or Licensor) a California corporation whose address is 1600 Broadway, Suite 1600, Denver, Colorado 80202 and Patients Mutual Assistance Collective Corporation, a California corporation dba Harborside Health Center (Harborside or Licensee) located at 1840 Embarcadero, Oakland, California 94606. UCANN and Licensee may be referred to herein collectively as the Parties on the following terms:

TERM SHEET FOR Prana Bio Nutrient Medicinals Distribution and Licensing Agreement (March 7th, 2017)

This Term Sheet is to definitively agree to a Distribution and Licensing Agreement by and between UCANN California Corporation, (UCANN or Licensor) a California corporation whose address is 1600 Broadway, Suite 1600, Denver, Colorado 80202 and Patients Mutual Assistance Collective Corporation, a California corporation dba Harborside Health Center (Harborside or Licensee) located at 1840 Embarcadero, Oakland, California 94606. UCANN and Licensee may be referred to herein collectively as the Parties on the following terms:

TERM SHEET FOR Prana Bio Nutrient Medicinals Distribution and Licensing Agreement (February 24th, 2017)

This Term Sheet is to definitively agree to a Distribution and Licensing Agreement by and between UCANN California Corporation, (UCANN or Licensor) a California corporation whose address is 1600 Broadway, Suite 1600, Denver, Colorado 80202 and Patients Mutual Assistance Collective Corporation, a California corporation dba Harborside Health Center (Harborside or Licensee) located at 1840 Embarcadero, Oakland, California 94606. UCANN and Licensee may be referred to herein collectively as the Parties on the following terms:

Immunomedics, Inc. – Immunomedics Enters Into Exclusive Global Licensing Agreement With Seattle Genetics for Sacituzumab Govitecan (IMMU-132) With Potential Payments of Up to Approximately $2 Billion, Plus Royalties Immunomedics to Receive $250 Million in Upfront Cash Payment; Plus Among Other Milestone Payments, an Additional $50 Million or Negotiated Economic Splits Relating to Rights Outside US, Canada and EU Agreement Provides for Seattle Genetics to Develop, Manufacture and Commercialize IMMU-132 in Multiple Indications; Immunomedics Retains Rights to Co-Promote in the United States Seattle Genetics to Make U (February 16th, 2017)

Morris Plains, N.J., February 10, 2017 Immunomedics, Inc. (NASDAQ: IMMU) (Immunomedics) today announced that it has entered into an exclusive global licensing agreement with Seattle Genetics, Inc. (NASDAQ: SGEN), an innovative global biotechnology company that develops and commercializes novel antibody-drug conjugates (ADCs) for the treatment of cancer. Under the agreement, Seattle Genetics will develop, fund, manufacture and commercialize IMMU-132, Immunomedics proprietary solid tumor therapy candidate.

Allergan Enters Into Licensing Agreement With Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs -- Expands Allergan's Innovative GI Pipeline With ABI-M201 and ABI-M301, Preclinical Compounds Targeting Ulcerative Colitis and Crohn's Disease, as Well as Future Compounds for Irritable Bowel Syndrome -- (January 10th, 2017)

DUBLIN, IRELAND and INDIANAPOLIS, INDIANA (USA) - January 9, 2017 - Allergan plc (NYSE: AGN) and Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced that Allergan has entered into a research, development, collaboration and license agreement for the worldwide rights to Assembly's microbiome gastrointestinal (GI) development programs. The agreement provides Allergan with worldwide rights to preclinical compounds ABI-M201 and ABI-M301, targeting ulcerative colitis (UC) and Crohn's disease (CD), as well as two additional compounds to be identified by Assembly for Irritable Bowel Syndromes (IBS); with Diarrhea (IBS-D), with Constipation (IBS-C) or Mixed (IBS-M).

China Gewang Biotechnology, Inc. – Licensing Agreement (November 14th, 2016)

On the basis of the principle of mutual complementarities and mutual benefits, Party A agrees Party B to use the recipe of xikang capsule, xizhi capsule and organic selenium powder to promote the mutual prosperity and development and realize the goal of win-win cooperation. According to the stipulation of Contract Law of People's Republic of China and relevant laws and regulations, and after friendly negotiation, both parties reach the following articles in order to comply mutually.

HYBRID Coating Technologies Inc. – Twelfth Amendment to the Licensing Agreement Previously Entered Into (November 9th, 2016)

Nanotech Industries International Inc., a Nevada corporation (and a wholly owned subsidiary of Hybrid Coating Technologies Inc.)

Software Licensing Agreement (November 4th, 2016)

This Software Licensing Agreement (Agreement) is effective as of November 2nd, 2016 (Effective Date), by and between SiteHelix Inc., a Delaware corporation, with its corporate office located at 3139 Old Mill Circle, Salt Lake City, Utah 84121 (SiteHelix), and Overstock.com, Inc., a Delaware corporation, with a place of business at 799 W. Coliseum Way, Midvale, Utah 84047 (Overstock). The parties agree as follows:

Nuvilex Inc – Second Amendment to Licensing Agreement (July 29th, 2016)

This Second Amendment to Licensing Agreement ("Second Amendment") is to memorialize the agreement between PharmaCyte Biotech, Inc.,formerly Nuvilex, Inc. ("Licensee"), and Austrianova Singapore Pte Ltd ("Licensor") to amend, effective as of 19 October 2015, the Licensing Agreement between the Parties dated as of 1 December 2014 ("Licensing Agreement") as set forth below . Defined terms in the Licensing Agreement have the same meaning as the terms in this Second Amendment.

Ligand Announces Multi-Program LTP Technology Licensing Agreement With Nucorion Pharmaceuticals (July 29th, 2016)

SAN DIEGO (July 29, 2016) - Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement for three programs utilizing Ligand's LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, Inc., a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China.

Nuvilex Inc – First Amendment to Licensing Agreement (July 29th, 2016)

This First Amendment to Licensing Agreement ("First Amendment") is to memorialize the agreement between PharmaCyte Biotech, Inc., formerly Nuvilex, Inc. ("Licensee") and Austrianova Singapore Pte Ltd ("Licensor") to amend, effective as of June 30, 2015, the Licensing Agreement between the parties dated as of 1 December 2014 ("Licensing Agreement") as follows. The defined terms in the Licensing Agreement have the same meaning as the terms in this First Amendment.

Nuvilex Inc – First Amendment to Licensing Agreement (July 29th, 2016)

This First Amendment to Licensing Agreement ("First Amendment") is to memorialize the agreement between PharmaCyte Biotech, Inc., formerly Nuvilex, Inc. ("Licensee"), and Austrianova Singapore Pte Ltd ("Licensor") to amend, effective as of 24 June 2016, the Licensing Agreement between the parties entered into as of June 25th, 2013 ("Licensing Agreement") as follows.

3DIcon Announces the Signing of Exclusive Licensing Agreement Between Its Merger Partner, Coretec Industries LLC, and NDSU Research Foundation (June 30th, 2016)

Licensing agreement provides Coretec and 3DIcon access to IP portfolio of silicon-based materials technology for development and commercialization

Pocket Shot Co – Amendment Number One to Licensing Agreement (June 16th, 2016)

THIS AMENDMENT NUMBER ONE TO LICENSING AGREEMENT ("First Amendment") is effective January 31, 2012 ("Effective Date"), and amends that certain Licensing Agreement (the "Agreement") entered into the 28th day of February, 2007, by and between Pocket Shot LLC, a Colorado limited liability company ("Licensor"), and Frank-Lin Distillers Products, Ltd, a California corporation ("Licensee").

Kore Resources Inc. – Software Licensing Agreement (June 10th, 2016)

THIS SOFTWARE LICENSE AGREEMENT is entered into this June 10, 2016 ("Agreement") , by and among ABCG Holdings Ltd., a corporation registered in Malta, EU, as the licensor (the "Licensor"), and Uneeqo Ltd., a corporation registered in the United Kingdom, as the licensee (the "Licensee"), and Uneeqo, Inc., a corporation incorporated in the state of Nevada in the United States and the sole owner of Licensee (the "Parent Company"). Licensor, Licensee and Parent Company may be referred to in this Agreement collectively as "Parties" or individually as a "Party".

STL Marketing Group, Inc. – Camposagrado, Inc. & STL Marketing Group, Inc. Patent & Trademark Licensing Agreement (June 8th, 2016)

THIS AGREEMENT, effective this 11th day, of February 2016, is entered into by Camposagrado, Inc. (hereinafter "LICENSOR") and STL Marketing Group, Inc. (hereinafter "LICENSEE").

TripBorn, Inc. – Software Licensing Agreement (April 18th, 2016)

SUNALPHA GREEN TECHNOLOGIES PRIVATE LIMITED ("Licensee") a company incorporated under the Companies Act 1956, having its registered office address: 812 Venus Atlantis Corporate Park, Prahladnagar, Ahmedabad, Guajrat, India 380015, hereinafter referred to as "Licensee" which expression shall, unless repugnant to the context and meaning thereof, include its successors, administrators and assigns

Settlement and Licensing Agreement (March 30th, 2016)

DataSci, LLC ("DataSci"), a Maryland limited liability company with its principle place of business located at 18111 Prince Philip Drive, Olney, Maryland 20810; and